NIRAMAI Health Analytix

company

About

NIRAMAI has developed a novel breast cancer screening solution that uses Thermalytix.

  • 1 - 10

Details

Last Funding Type
Seed
Industries
Health Care,Hospital
Founded date
Jan 1, 2016
Number Of Employee
1 - 10
Operating Status
Active

Breast Cancer is the leading type of cancer in women. According to WHO, one in every 8 women in US is at the risk of developing a breast abnormality in her life time. It is well-established that early diagnosis is very critical in saving a life of a cancer patient. They at NIRAMAI have developed a new cancer screening software that uses machine intelligence over thermography images to enable a low cost, easy to use, portable solution and requires minimal human supervision. Their solution can detect cancer at a much earlier stage than traditional diagnostic methods and self-examination and can therefore improve survival rates. Their method of breast cancer screening can detect tumors 5 times smaller than what clinical exam can detect, is non-contact, painless and free of any radiation, apart from being low-cost, and universally accessible. With their solution, women of all age groups can undergo frequent screening without any side-effects.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
NIRAMAI Health Analytix has raised a total of — in funding over 2 rounds. Their latest funding was raised on Apr 24, 2017 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 24, 2017 Seed 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
NIRAMAI Health Analytix is funded by 1 investors. 500 Global are the most recent investors.
Investor Name Lead Investor Funding Round
500 Global Seed